Fortress Biotech Appoints David Jin as Chief Financial Officer
July 22, 2022 08:00 ET
|
Fortress Biotech, Inc.
MIAMI, July 22, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States
May 31, 2022 08:30 ET
|
Fortress Biotech, Inc.
Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor in clinical development at Fortress’ subsidiary company, UR-1 Therapeutics Dotinurad (URECE® tablet) was approved in Japan...
Fortress Biotech to Participate in Two Upcoming May 2022 Investor Conferences
May 18, 2022 08:30 ET
|
Fortress Biotech, Inc.
MIAMI, May 18, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
May 12, 2022 16:01 ET
|
Fortress Biotech, Inc.
Net revenue for first quarter of 2022 increased 106% period-over-period to $23.9 million, a company quarterly record Positive topline results from registration-enabling study of cosibelimab in...
Fortress Biotech to Present at the 21st Annual Needham Virtual Healthcare Conference
April 07, 2022 08:30 ET
|
Fortress Biotech, Inc.
MIAMI, April 07, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022
April 01, 2022 08:30 ET
|
Fortress Biotech, Inc.
MIAMI, April 01, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights
March 28, 2022 08:00 ET
|
Fortress Biotech, Inc.
Record 2021: Net revenue of $68.8 million and proceeds from the successful monetization of our investment in Caelum Biosciences of $56.9 million1 2021 net loss attributable to common...
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting
March 21, 2022 08:00 ET
|
Fortress Biotech, Inc.
Cyprium Therapeutics, a subsidiary of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes diseaseCUTX-101 has potential to be first FDA-approved treatment for Menkes disease; rolling...
Fortress Biotech to Participate in Three March 2022 Investor Conferences
March 09, 2022 09:00 ET
|
Fortress Biotech, Inc.
MIAMI, March 09, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022
March 03, 2022 08:00 ET
|
Fortress Biotech, Inc.
MIAMI, March 03, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...